Newsletter

[ Vol. 11 No. 3 ] (September - December 2010 )
"Enteric DialysisTM" - Brief introduction and its potential for chronic kidney disease (CKD) applications

Natarajan Ranganathan
Kibow Biotech Inc., Newtown Square, Pennsylvania, USA

This session will brief on the scientific rationale in developing a viable and effective oral probiotic - a beneficial microbial product formulation with several uremic toxin removal capabilities towards human kidney failure applications. By offering an affordable, readily available and easy-to-administer dietary/nutritional supplement product this probiotic formulation is expected to target renal failure patients worldwide. This human population is in need of an alternative and effective complementary oral product, which will alleviate uremic symptoms and potentially help to slow down or delay the progression of the kidney failure to its final stages requiring dialysis or transplantation.

Efforts in using a probiotic nutritional product formulation have been very successful in unexplored and totally unanticipated veterinary applications in geriatric cats and dogs with moderate to severe kidney failure conditions. The next step is evaluating the probiotic formulation in human Chronic Kidney Failure patients universally. All data collected so far warrants making this step, which will enhance and validate the concept of “Enteric Dialysis^®” and bring an easy to use, affordable and minimally invasive product to the CKD patient population worldwide. When clinically tested and fully validated the unique microbial product formulation may also possess an excellent potential to possibly reduce the duration or frequency of hemo or peritoneal dialysis in the End Stage Renal Disease (ESRD) patients worldwide.

General outline of this presentations will be:(A) Current study hypothesis (B) Brief introduction on the microbial eco-flora of the large bowel (C) introduction to Probiotics and currently used probiotic in human clinical applications, (D) Summary of research and development work - In vitro lab studies and with Simulated Human Intestinal Microbial Ecosystem (SHIME) gastrointestinal machine data, (E). 5/6 Nephrectomized Rodent and Minipig studies, (F) Cats and dogs in kidney failure, (G) Human volunteer safety study, (H) on going multi-site pilot scale studies and interim data analysis and, (I) Summary and Conclusions.

 
From  
PENSA 2009
“Energizing Nutrition Support Practice for Life”
June 5-7 2009, Shangri-La Hotel, Kuala Lumpur, Malaysia 
Page: 59